Yamashita Y, Takahashi M, Bussaka H, Fukushima S, Kawaguchi T, Nakano M
Department of Radiology, Kumamoto University School of Medicine, Japan.
Cancer. 1989 Dec 15;64(12):2437-44. doi: 10.1002/1097-0142(19891215)64:12<2437::aid-cncr2820641207>3.0.co;2-h.
The drug 5-fluoro-2-deoxyuridine-C8 (FUdR-C8), one of the lipophilic prodrugs of FUdR, was dissolved in an oily lymphographic agent (Lipiodol Ultra Fluid, Andre Gelbe Laboratory, Paris, France; Ethiodol, Savage Laboratories, Melville, NY) and used for the intraarterial treatment of malignant liver tumors. From August 1985 to June 1988, 33 patients with hepatocellular carcinoma and 13 patients with metastatic liver tumors were treated with this agent at the Kumamoto University Hospital and its affiliated hospitals. The response rate (complete remission [CR] and partial remission [PR]) was 27.6% for hepatocellular carcinomas and 46.1% for metastatic liver tumors. The cumulative 1-year survival rate was 55.1% for hepatocellular carcinomas and 70.0% for metastatic liver tumors. More than a 50% decrease in the tumor marker level was observed in ten of 21 patients with hepatocellular carcinoma and in two of eight patients with metastatic liver tumors. The side effects, which were transient and controlled with conservative treatment, included fever, abdominal pain, nausea, vomiting, and acute gastritis.
药物5-氟-2-脱氧尿苷-C8（FUdR-C8）是FUdR的亲脂性前体药物之一，溶于油性淋巴造影剂（超液态碘油，法国巴黎安德烈·盖尔贝实验室；乙碘油，美国纽约梅尔维尔萨维奇实验室），用于恶性肝肿瘤的动脉内治疗。1985年8月至1988年6月，熊本大学医院及其附属医院用该药物治疗了33例肝细胞癌患者和13例转移性肝肿瘤患者。肝细胞癌的缓解率（完全缓解[CR]和部分缓解[PR]）为27.6%，转移性肝肿瘤为46.1%。肝细胞癌的1年累积生存率为55.1%，转移性肝肿瘤为70.0%。21例肝细胞癌患者中有10例、8例转移性肝肿瘤患者中有2例的肿瘤标志物水平下降超过50%。副作用为一过性，通过保守治疗可控制，包括发热、腹痛、恶心、呕吐和急性胃炎。
